FDA Inspection 1073537 — Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc. — FEI 1219205

The FDA completed an inspection of Boehringer Ingelheim Pharmaceuticals, Inc. on Dec 6, 2018 in Ridgefield, CT. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Dec 6, 2018
Fiscal Year
2019
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Ridgefield, CT (United States)

Additional Details

Sponsor, Contract Research Organization

Citations

IDCFRDescription
748221 CFR 312.50General responsibilities of sponsors

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.